133 results on '"Jonckheere, Nicolas"'
Search Results
2. Mucin expression, epigenetic regulation and patient survival: A toolkit of prognostic biomarkers in epithelial cancers
- Author
-
Jonckheere, Nicolas, Vincent, Audrey, Neve, Bernadette, and Van Seuningen, Isabelle
- Published
- 2021
- Full Text
- View/download PDF
3. Long non-coding RNAs: the tentacles of chromatin remodeler complexes
- Author
-
Neve, Bernadette, Jonckheere, Nicolas, Vincent, Audrey, and Van Seuningen, Isabelle
- Published
- 2021
- Full Text
- View/download PDF
4. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting
- Author
-
Jonckheere, Nicolas, Vasseur, Romain, and Van Seuningen, Isabelle
- Published
- 2017
- Full Text
- View/download PDF
5. Long-term consequences of one anastomosis gastric bypass on esogastric mucosa in a preclinical rat model
- Author
-
Siebert, Matthieu, Ribeiro-Parenti, Lara, Nguyen, Nicholas D., Hourseau, Muriel, Duchêne, Belinda, Humbert, Lydie, Jonckheere, Nicolas, Nuel, Grégory, Chevallier, Jean-Marc, Duboc, Henri, Rainteau, Dominique, Msika, Simon, Kapel, Nathalie, Couvelard, Anne, Bado, André, and Le Gall, Maude
- Published
- 2020
- Full Text
- View/download PDF
6. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice.
- Author
-
Quilbe, Alexandre, Mustapha, Rami, Duchêne, Belinda, Kumar, Abhishek, Werkmeister, Elisabeth, Leteurtre, Emmanuelle, Moralès, Olivier, Jonckheere, Nicolas, Van Seuningen, Isabelle, and Delhem, Nadira
- Subjects
PANCREATIC intraepithelial neoplasia ,PANCREATIC tumors ,TRANSGENIC mice ,REGULATORY T cells ,IMMUNE checkpoint inhibitors ,PRECANCEROUS conditions ,T cells - Abstract
Background: Pancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a variety of solid tumors, but most clinical trials have failed to demonstrate clinical efficacy in PDAC. This low efficacy is partly explained by a highly immunosuppressive microenvironment, which dampens anti-tumor immunity through the recruitment or induction of immunosuppressive cells, particularly regulatory T cells (Tregs). In this context, our laboratory has developed a novel immunotherapeutic strategy aimed at inhibiting the suppressive activity of Tregs, based on a patented (EP3152234B1) monoclonal antibody (mAb) targeting galectin-9 (LGALS9). Materials and methods: CD4+ conventional T cells (TCD4 or Tconv), Treg ratio, and LGALS9 expression were analyzed by immunohistochemistry (IHC) and cytometry in blood and pancreas of K-rasLSL.G12D/+;Pdx-1-Cre (KC) and KrasWildType (WT);Pdx1-Cre (WT) mice aged 4-13 months. Pancreatic intraepithelial neoplasm (PanIN) progression and grade were quantified using FIJI software and validated by pathologists. The anti-galectin-9 mAb was validated for its use in mice on isolated murine C57BL/6 Treg by immunofluorescence staining and cytometry. Its specificity and functionality were validated in proliferation assays on rLGALS9-immunosuppressed murine Tconv and in suppression assays between murine Treg and Tconv. Finally, 2-month-old KC mice were treated with anti-LGALS9 and compared to WT mice for peripheral and infiltrating TCD4, Treg, and PanIN progression. Results: IHC and cytometry revealed a significant increase in LGALS9 expression and Treg levels in the blood and pancreas of KC mice proportional to the stages of precancerous lesions. Although present in WT mice, LGALS9 is expressed at a basal level with low and restricted expression that increases slightly over time, while Treg cells are few in number in their circulation and even absent from the pancreas over time. Using our anti-LGALS9 mAb in mice, it is shown that (i) murine Treg express LGALS9, (ii) the mAb could target and inhibit recombinant murine LGALS9, and (iii) neutralize murine Treg suppressive activity. Finally, the anti-LGALS9 mAb in KC mice reduced (i) LGALS9 expression in pancreatic cancer cells, (ii) the Treg ratio, and (iii) the total surface area and grade of PanIN. Conclusion: We demonstrate for the first time that an anti-LGALS9 antibody, by specifically targeting endogenous LGALS9 tumor and exogenous LGALS9 produced by Treg, was able to limit the progression of pancreatic neoplastic lesions in mice, opening up new prospects for its use as an immunotherapeutic tool in PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?
- Author
-
Jannin, Arnaud, Dessein, Anne-Frédérique, Do Cao, Christine, Vantyghem, Marie-Christine, Chevalier, Benjamin, Van Seuningen, Isabelle, Jonckheere, Nicolas, and Coppin, Lucie
- Subjects
PANCREATIC tumors ,NEUROENDOCRINE tumors ,AMINO acid metabolism ,KREBS cycle ,GENE expression profiling ,METABOLISM - Abstract
Introduction: Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrine tumors (pNETs) has focused on genetic and epigenetic modifications and related signaling pathways, but few studies have been devoted to characterizing the metabolic profile of these tumors. In this review, we thoroughly investigate the metabolic pathways in pNETs by analyzing the transcriptomic and metabolomic data available in the literature. Methodology: We retrieved and downloaded gene expression profiles from all publicly available gene set enrichments (GSE43797, GSE73338, and GSE117851) to compare the differences in expressed genes based on both the stage and MEN1 mutational status. In addition, we conducted a systematic review of metabolomic data in NETs. Results: By combining transcriptomic and metabolomic approaches, we have identified a distinctive metabolism in pNETs compared with controls without pNETs. Our analysis showed dysregulations in the one-carbon, glutathione, and polyamine metabolisms, fatty acid biosynthesis, and branched-chain amino acid catabolism, which supply the tricarboxylic acid cycle. These targets are implicated in pNET cell proliferation and metastasis and could also have a prognostic impact. When analyzing the profiles of patients with or without metastasis, or with or without MEN1 mutation, we observed only a few differences due to the scarcity of published clinical data in the existing research. Consequently, further studies are now necessary to validate our data and investigate these potential targets as biomarkers or therapeutic solutions, with a specific focus on pNETs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Cryosectioning the intestinal crypt-villus axis: An ex vivo method to study the dynamics of epigenetic modifications from stem cells to differentiated cells
- Author
-
Vincent, Audrey, Kazmierczak, Catherine, Duchêne, Belinda, Jonckheere, Nicolas, Leteurtre, Emmanuelle, and Van Seuningen, Isabelle
- Published
- 2015
- Full Text
- View/download PDF
9. Mucins and tumor resistance to chemotherapeutic drugs
- Author
-
Jonckheere, Nicolas, Skrypek, Nicolas, and Van Seuningen, Isabelle
- Published
- 2014
- Full Text
- View/download PDF
10. Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas
- Author
-
Jonckheere, Nicolas and Van Seuningen, Isabelle
- Published
- 2018
- Full Text
- View/download PDF
11. Helicobacter pylori urease and flagellin alter mucin gene expression in human gastric cancer cells
- Author
-
Perrais, Michaël, Rousseaux, Christel, Ducourouble, Marie-Paule, Courcol, René, Vincent, Pascal, Jonckheere, Nicolas, and Van Seuningen, Isabelle
- Published
- 2014
- Full Text
- View/download PDF
12. Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival
- Author
-
Desurmont, Thibault, Skrypek, Nicolas, Duhamel, Alain, Jonckheere, Nicolas, Millet, Guillaume, Leteurtre, Emmanuelle, Gosset, Pierre, Duchene, Belinda, Ramdane, Nassima, Hebbar, Mohamed, Van Seuningen, Isabelle, Pruvot, François-René, Huet, Guillemette, and Truant, Stéphanie
- Published
- 2015
- Full Text
- View/download PDF
13. TRPM7 Modulates Human Pancreatic Stellate Cell Activation.
- Author
-
Auwercx, Julie, Kischel, Philippe, Lefebvre, Thibaut, Jonckheere, Nicolas, Vanlaeys, Alison, Guénin, Stéphanie, Radoslavova, Silviya, Van Seuningen, Isabelle, Ouadid-Ahidouch, Halima, Kocher, Hemant M., Dhennin-Duthille, Isabelle, and Gautier, Mathieu
- Subjects
PANCREATIC duct ,LIVER cells ,FIBROBLASTS ,PANCREATIC diseases ,PI3K/AKT pathway ,CELL cycle - Abstract
Pancreatic diseases, such as pancreatitis or pancreatic ductal adenocarcinoma, are characterized by the presence of activated pancreatic stellate cells (PSCs). These cells represent key actors in the tumor stroma, as they actively participate in disease development and progression: reprograming these PSCs into a quiescent phenotype has even been proposed as a promising strategy for restoring the hallmarks of a healthy pancreas. Since TRPM7 channels have been shown to regulate hepatic stellate cells proliferation and survival, we aimed to study the role of these magnesium channels in PSC activation and proliferation. PS-1 cells (isolated from a healthy pancreas) were used as a model of healthy PSCs: quiescence or activation were induced using all-trans retinoic acid or conditioned media of pancreatic cancer cells, respectively. The role of TRPM7 was studied by RNA silencing or by pharmacological inhibition. TRPM7 expression was found to be correlated with the activation status of PS-1 cells. TRPM7 expression was able to regulate proliferation through modulation of cell cycle regulators and most importantly p53, via the PI3K/Akt pathway, in a magnesium-dependent manner. Finally, the analysis of TCGA database showed the overexpression of TRPM7 in cancer-associated fibroblasts. Taken together, we provide strong evidences that TRPM7 can be considered as a marker of activated PSCs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Analysis of mPygo2 mutant mice suggests a requirement for mesenchymal Wnt signaling in pancreatic growth and differentiation
- Author
-
Jonckheere, Nicolas, Mayes, Erin, Shih, Hung-Ping, Li, Boan, Lioubinski, Oleg, Dai, Xing, and Sander, Maike
- Subjects
Stem cells -- Growth ,Company growth ,Biological sciences - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ydbio.2008.03.014 Byline: Nicolas Jonckheere (a), Erin Mayes (a), Hung-Ping Shih (a), Boan Li (b), Oleg Lioubinski (a), Xing Dai (b), Maike Sander (a) Keywords: Pygopus; Wnt; Pancreas development; Mesenchyme; Islet; Endocrine; Proliferation; Differentiation; Mouse Abstract: Pygopus has recently been identified in Drosophila as an essential component of the nuclear complex required for canonical Wnt signaling. Here, we have investigated the role of the mammalian pygopus ortholog, mPygo2, in pancreas development. We show that a null mutation of mPygo2 in mice causes pancreas hypoplasia due to decreased progenitor cell proliferation after embryonic day (e) 12.5. During the same time window, mPygo2-deficient embryos begin to display a reduction in endocrine progenitors and consequently a decrease in islet endocrine cell mass. Consistent with its function after e12.5, late-developing endocrine cell types, such as beta, delta and PP cells, are specifically reduced, while the earlier-forming alpha cells develop normally. We find canonical Wnt signaling to be predominantly active in the mesenchyme at the time when mPygo2 is required and demonstrate the dependence of Wnt signal transduction on mPygo2. Furthermore, conditional deletion of mPygo2.sup.flox allele in the pancreatic epithelium does not phenocopy the defects in mPygo2-null mutants. Since mPygo2 is expressed in the pancreatic mesenchyme and the role of the mesenchyme in epithelial progenitor cell expansion is well documented, our findings suggest an indirect role for mPygo2 in epithelial growth and differentiation through regulation of mesenchymal signals. Together, our data suggest a previously unappreciated role for mesenchymal Wnt signaling in regulating pancreatic organ growth and cell differentiation. Author Affiliation: (a) Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA 92697-2300, USA (b) Department of Biological Chemistry, University of California Irvine, Irvine, CA 92697-1700, USA Article History: Received 23 October 2007; Revised 10 February 2008; Accepted 3 March 2008
- Published
- 2008
15. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-β in pancreatic carcinogenesis
- Author
-
Jonckheere, Nicolas, Perrais, Michaël, Mariette, Christophe, Batra, Surinder K, Aubert, Jean-Pierre, Pigny, Pascal, and Van Seuningen, Isabelle
- Published
- 2004
- Full Text
- View/download PDF
16. Inositol (1,4,5)-Trisphosphate Receptors in Invasive Breast Cancer: A New Prognostic Tool?
- Author
-
Foulon, Arthur, Rybarczyk, Pierre, Jonckheere, Nicolas, Brabencova, Eva, Sevestre, Henri, Ouadid-Ahidouch, Halima, and Rodat-Despoix, Lise
- Subjects
CANCER invasiveness ,PROGRESSION-free survival ,PROGNOSTIC tests ,BREAST cancer ,INOSITOL ,HORMONE receptors ,RYANODINE receptors ,CANCER cells - Abstract
Simple Summary: The inositol-trisphosphate receptor (IP
3 R) is a key player in physiological and pathological intracellular calcium signaling. The objective of the present study was to assess the putative value of the three IP3 R subtypes as prognostic biomarkers in breast cancer. We found that IP3 R3 is the most strongly expressed subtype in breast cancer tissue. Furthermore, IP3 R3 and IP3 R1 are significantly more expressed in invasive breast cancer tissue than in non-tumor tissue. In contrast to IP3 R1 and IP3 R2, the expression of IP3 R3 was positively correlated with prognostic factors including tumor size, regional node invasion, histologic grade, proliferation index, and hormonal status. By analyzing public databases, we found that the expression of all IP3 R subtypes is significantly correlated with the overall survival and disease-free survival of patients with breast cancer. We conclude that relative to the other two IP3 R subtypes, IP3 R3 expression is upregulated in breast cancer and is correlated with prognostic factors. We strongly believe that our results will open up new perspectives with regard to the link between IP3 Rs and breast cancer aggressiveness. Breast cancer is the leading cause of cancer death among women in worldwide and France. The disease prognosis and treatment differ from one breast cancer subtype to another, and the disease outcome depends on many prognostic factors. Deregulation of ion flux (especially Ca2+ flux) is involved in many pathophysiology processes, including carcinogenesis. Inside the cell, the inositol-trisphosphate receptor (IP3 R) is a major player in the regulation of the Ca2+ flux from the endoplasmic reticulum to the cytoplasm. The IP3 Rs (and particularly the IP3 R3 subtype) are known to be involved in proliferation, migration, and invasion processes in breast cancer cell lines. The objective of the present study was to evaluate the potential value of IP3 Rs as prognostic biomarkers in breast cancer. We found that expression levels of IP3 R3 and IP3 R1 (but not IP3 R2) were significantly higher in invasive breast cancer of no special type than in non-tumor tissue from the same patient. However, the IP3 R3 subtype was expressed more strongly than the IP3 R1 and IP3 R2 subtypes. Furthermore, the expression of IP3 R3 (but not of IP3 R1 or IP3 R2) was positively correlated with prognostic factors such as tumor size, regional node invasion, histologic grade, proliferation index, and hormone receptor status. In an analysis of public databases, we found that all IP3 Rs types are significantly associated with overall survival and progression-free survival in patients with breast cancer. We conclude that relative to the other two IP3 R subtypes, IP3 R3 expression is upregulated in breast cancer and is correlated with prognostic factors. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. The mouse Muc5b mucin gene is transcriptionally regulated by thyroid transcription factor-1 (TTF-1) and GATA-6 transcription factors
- Author
-
Jonckheere, Nicolas, Velghe, Amélie, Ducourouble, Marie-Paule, Copin, Marie-Christine, Renes, Ingrid B., and Van Seuningen, Isabelle
- Published
- 2011
- Full Text
- View/download PDF
18. A new pancreatic adenocarcinoma‐derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
- Author
-
Hadj Bachir, Elsa, Poiraud, Charles, Paget, Sonia, Stoup, Nicolas, El Moghrabi, Soumaya, Duchêne, Belinda, Jouy, Nathalie, Bongiovanni, Antonino, Tardivel, Meryem, Weiswald, Louis‐Bastien, Vandepeutte, Marie, Beugniez, César, Escande, Fabienne, Leteurtre, Emmanuelle, Poulain, Laurent, Lagadec, Chann, Pigny, Pascal, Jonckheere, Nicolas, Renaud, Florence, and Truant, Stephanie
- Subjects
CANCER chemotherapy ,DRUG resistance in cancer cells ,PROGNOSIS ,DRUG resistance ,DRUG therapy ,ANTIMETABOLITES - Abstract
Background Information: Although improvements have been made in the management of pancreatic adenocarcinoma (PDAC) during the past 20 years, the prognosis of this deadly disease remains poor with an overall 5‐year survival under 10%. Treatment with FOLFIRINOX, a combined regimen of 5‐fluorouracil, irinotecan (SN‐38) and oxaliplatin, is nonetheless associated with an excellent initial tumour response and its use has allowed numerous patients to go through surgery while their tumour was initially considered unresectable. These discrepancies between initial tumour response and very low long‐term survival are the consequences of rapidly acquired chemoresistance and represent a major therapeutic frontier. To our knowledge, a model of resistance to the combined three drugs has never been described due to the difficulty of modelling the FOLFIRINOX protocol both in vitro and in vivo. Patient‐derived tumour organoids (PDO) are the missing link that has long been lacking in the wide range of epithelial cancer models between 2D adherent cultures and in vivo xenografts. In this work we sought to set up a model of PDO with resistance to FOLFIRINOX regimen that we could compare to the paired naive PDO. Results: We first extrapolated physiological concentrations of the three drugs using previous pharmacodynamics studies and bi‐compartmental elimination models of oxaliplatin and SN‐38. We then treated PaTa‐1818x naive PDAC organoids with six cycles of 72 h‐FOLFIRINOX treatment followed by 96 h interruption. Thereafter, we systematically compared treated organoids to PaTa‐1818x naive organoids in terms of growth, proliferation, viability and expression of genes involved in cancer stemness and aggressiveness. Conclusions: We reproductively obtained resistant organoids FoxR that significantly showed less sensitivity to FOLFORINOX treatment than the PaTa‐1818x naive organoids from which they were derived. Our resistant model is representative of the sequential steps of chemoresistance observed in patients in terms of growth arrest (proliferation blockade), residual disease (cell quiescence/dormancy) and relapse. Significance: To our knowledge, this is the first genuine in vitro model of resistance to the three drugs in combined therapy. This new PDO model will be a great asset for the discovery of acquired chemoresistance mechanisms, knowledge that is mandatory before offering new therapeutic strategies for pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press
- Author
-
Jonckheere, Nicolas and Van Seuningen, Isabelle
- Published
- 2014
- Full Text
- View/download PDF
20. Of autophagy and in vivo pancreatic carcinogenesis: The p53 status matters!
- Author
-
Jonckheere, Nicolas, Vincent, Audrey, and Van Seuningen, Isabelle
- Published
- 2014
- Full Text
- View/download PDF
21. Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/β-catenin pathway.
- Author
-
Lahdaoui, Fatima, Messager, Mathieu, Vincent, Audrey, Hec, Flora, Gandon, Anne, Warlaumont, Maxime, Renaud, Florence, Leteurtre, Emmanuelle, Piessen, Guillaume, Jonckheere, Nicolas, Mariette, Christophe, and Van Seuningen, Isabelle
- Subjects
MUCINS ,TUMOR prognosis ,CANCER ,TUMOR growth ,CARCINOGENESIS - Abstract
Secreted mucins are large O-glycosylated proteins that participate in the protection/ defence of underlying mucosae in normal adults. Alteration of their expression is a hallmark of numerous epithelial cancers and has often been correlated to bad prognosis of the tumour. The secreted mucin MUC5B is overexpressed in certain subtypes of gastric and intestinal cancers, but the consequences of this altered expression on the cancer cell behaviour are not known. To investigate the role of MUC5B in carcinogenesis, its expression was knocked-down in the human gastric cancer cell line KATO-III and in the colonic cancer cell line LS174T by using transient and stable approaches. Consequences of MUC5B knocking-down on cancer cells were studied with respect to in vitro proliferation, migration and invasion, and in vivo on tumour growth using a mouse subcutaneous xenograft model. Western blotting, luciferase assay and qRT--PCR were used to identify proteins and signalling pathways involved. In vitro MUC5B down-regulation leads to a decrease in proliferation, migration and invasion properties in both cell lines. Molecular mechanisms involved the alteration of β-catenin expression, localization and activity and decreased expression of several of its target genes. In vivo xenografts of MUC5B-defi- cient cells induced a decrease in tumour growth when compared with MUC5B-expressing Mock cells. Altogether, the present study shows that down-regulation of MUC5B profoundly alters proliferation, migration and invasion of human gastrointestinal cancer cells and that these alterations may be, in part, mediated by the Wnt/β-catenin pathway emphasizing the potential of MUC5B as an actor of gastrointestinal carcinogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Tif1γ Suppresses Murine Pancreatic Tumoral Transformation by a Smad4-Independent Pathway
- Author
-
Vincent, David F., Gout, Johann, Chuvin, Nicolas, Arfi, Vanessa, Pommier, Roxane M., Bertolino, Philippe, Jonckheere, Nicolas, Ripoche, Doriane, Kaniewski, Bastien, Martel, Sylvie, Langlois, Jean-Baptiste, Goddard-Léon, Sophie, Colombe, Amélie, Janier, Marc, Van Seuningen, Isabelle, Losson, Régine, Valcourt, Ulrich, Treilleux, Isabelle, Dubus, Pierre, Bardeesy, Nabeel, and Bartholin, Laurent
- Published
- 2012
- Full Text
- View/download PDF
23. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.
- Author
-
Vasseur, Romain, Skrypek, Nicolas, Duchêne, Belinda, Renaud, Florence, Martínez-Maqueda, Daniel, Vincent, Audrey, Porchet, Nicole, Van Seuningen, Isabelle, and Jonckheere, Nicolas
- Abstract
Copyright of BBA - Gene Regulatory Mechanisms is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
- Full Text
- View/download PDF
24. Evaluation of the expression of fatty acid synthase and O-GlcNAc transferase in patients with liver cancer by exploration of transcriptome databases and experimental approaches.
- Author
-
Raab, Sadia, Very, Ninon, Duchêne, Belinda, Rybarczyk, Pierre, Jonckheere, Nicolas, El Yazidi-Belkoura, Ikram, and Lefebvre, Tony
- Subjects
FATTY acid synthases ,LIVER cancer ,CANCER patients ,REVERSE transcriptase polymerase chain reaction ,RAPAMYCIN ,HEPATOCELLULAR carcinoma ,LIVER cells ,CALCINOSIS - Abstract
Tumor occurrence and development are closely related to metabolism abnormalities. One of the metabolic networks that is dysregulated during carcinogenesis is the fatty acid synthesis pathway, which is mainly controlled by fatty acid synthase (FASN). We previously demonstrated in proliferating HepG2 liver cancer cells that FASN expression depends on the catalytic activity of O-GlcNAc transferase (OGT) and the activation of the mechanistic/mammalian target of rapamycin (mTOR) pathway. The aim of the present study was to go further in these investigations by analyzing datasets and tissues of patients with liver cancer. To that purpose, transcriptome databases were explored, and reverse transcription-quantitative PCR, western blotting and immunohistochemistry were used. Database analyses revealed that FASN and OGT gene expression was higher in certain cancer tissues, including liver hepatocellular carcinoma, compared with that in non-cancerous tissues. At the protein level, FASN expression was higher in the liver cancer-derived cell lines HepG2 and Hep3B compared with the immortalized human hepatocytes IHH cell line. However, neither the expression of OGT nor of its product O-GlcNAcylation showed any significant difference among the three hepatic cell lines. Subsequently, the expression of FASN and OGT at the protein and mRNA levels was evaluated in human liver cancer and non-tumoral tissues from the same patients with different liver lesions. The results from western blotting demonstrated a significant increase in OGT ands O-GlcNAcylation expression in liver cancer tissues independently of the type of lesion characterizing the non-tumoral counterpart. As previously reported for HepG2 proliferating cells, the protein level of FASN was positively correlated with the activation of mTOR and, although a rather upward trend, a high variability in its expression was monitored between patients. However, the results from immunohistochemistry showed no particular modification for OGT and O-GlcNAcylation expression and a significant increase in FASN expression in cancer tissues compared with that in adjacent non-tumoral tissues. Non-significant changes were observed for FASN and OGT mRNA levels between tumoral and non-tumoral samples, with a high variability between patients. Taken together, these results demonstrated that FASN expression was higher in hepatic cancer tissues in comparison with non-tumoral tissues. Furthermore, OGT expression and activity were shown to vary greatly between cell or cancer type, making any generalization difficult. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Membrane-bound mucin modular domains: From structure to function.
- Author
-
Jonckheere, Nicolas, Skrypek, Nicolas, Frénois, Frédéric, and Van Seuningen, Isabelle
- Subjects
- *
MUCINS , *MEMBRANE proteins , *GLYCOPROTEINS , *OLIGOSACCHARIDES , *CELLULAR signal transduction , *CELL communication - Abstract
Abstract: Mucins belong to a heterogeneous family of large O-glycoproteins composed of a long peptidic chain called apomucin on which are linked hundreds of oligosaccharidic chains. Among mucins, membrane-bound mucins are modular proteins and have a structural organization usually containing Pro/Thr/Ser-rich O-glycosylated domains (PTS), EGF-like and SEA domains. Via these modular domains, the membrane-bound mucins participate in cell signalling and cell interaction with their environment in normal and pathological conditions. Moreover, the recent knowledge of these domains and their biological activities led to the development of new therapeutic approaches involving mucins. In this review, we show 3D structures of EGF and SEA domains. We also describe the functional features of the evolutionary conserved domains of membrane-bound mucins and discuss consequences of splice events. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
26. GATA-4/-6 and HNF-1/-4 families of transcription factors control the transcriptional regulation of the murine Muc5ac mucin during stomach development and in epithelial cancer cells.
- Author
-
Jonckheere, Nicolas, Vincent, Audrey, Franquet-Ansart, Hélène, Witte-Bouma, Janneke, Korteland-van Male, Anita, Leteurtre, Emmanuelle, Renes, Ingrid B., and Van Seuningen, Isabelle
- Subjects
REVERSE transcriptase ,POLYMERASE chain reaction ,HEPATOCYTE nuclear factors ,TRANSCRIPTION factors ,EPITHELIAL cell tumors ,GENE expression - Abstract
Abstract: During human embryonic and fetal development of the gastrointestinal tract, the gene encoding the MUC5AC mucin has a spatio–temporal pattern of expression restricted to the stomach. In order to better understand the molecular mechanisms responsible for this restricted pattern of expression, we have studied Muc5ac expression in the developing stomach of the mouse and correlated it to that of transcription factors known to be involved in cell differentiation programs during development. Our results indicate that GATA-6 and HNF-4α expression increased concomitantly with the induction of Muc5ac expression in embryonic stomach. We then studied Muc5ac transcriptional regulation by these transcription factors and showed that they all transactivate Muc5ac promoter. We also identified several active GATA-4/-5/-6 and HNF-1/-4 cis-elements using gel shift assays, chromatin immunoprecipitation and site-directed mutagenesis. Among all Muc5ac regulators, only GATA-6 and HNF-4a expression was concomitant to that of Muc5ac in the developing stomach. This is thus in favor of an important role for these two transcription factors as regulators of expression of the Muc5ac mucin during stomach development and in epithelial cancer cells. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
27. The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways.
- Author
-
Jonckheere, Nicolas, Skrypek, Nicolas, Merlin, Johann, Dessein, Anne Frédérique, Dumont, Patrick, Leteurtre, Emmanuelle, Harris, Ann, Desseyn, Jean-Luc, Susini, Christiane, Frénois, Frédéric, and Van Seuningen, Isabelle
- Subjects
- *
MUCINS , *GENETIC regulation , *CANCER cells , *PANCREATIC cancer , *ONCOGENES - Abstract
The mucin MUC4 and its membrane partner the ErbB2 oncogenic receptor are potential interacting partners in human pancreatic tumour development. However, the way they function is still largely unknown. In this work, we aimed to identify the cellular mechanisms and the intracellular signalling pathways under the control of both ErbB2 and MUC4 in a human pancreatic adenocarcinomatous cell line. Using co-immunoprecipitation and GST pull-down, we show that MUC4 and ErbB2 interact in the human pancreatic adenocarcinomatous cell line CAPAN-2 via the EGF domains of MUC4. Stable cell clones were generated in which either MUC4 or ErbB2 were knocked down (KD) by a shRNA approach. Biological properties of these cells were then studied in vitro and in vivo. Our results show that ErbB2-KD cells are more apoptotic and less proliferative (decreased cyclin D1 and increased p27kip1 expression) while migration and invasive properties were not altered. MUC4-KD clones were less proliferative with decreased cyclin D1 expression, G1 cell cycle arrest and altered ErbB2/ ErbB3 expression. Their migration properties were reduced whereas invasive properties were increased. Importantly, inhibition of ErbB2 and MUC4 expression did not impair the same signalling pathways (inhibition of MUC4 expression affected the JNK pathway whereas that of ErbB2 altered the MAPK pathway). Finally, ErbB2-KD and MUC4-KD cells showed impaired tumour growth in vivo. Our results show that ErbB2 and MUC4, which interact physically, activate different intracellular signalling pathways to regulate biological properties of CAPAN-2 pancreatic cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. The MUC4 membrane-bound mucin regulates esophageal cancer cell proliferation and migration properties: Implication for S100A4 protein
- Author
-
Bruyère, Emilie, Jonckheere, Nicolas, Frénois, Frédéric, Mariette, Christophe, and Van Seuningen, Isabelle
- Subjects
- *
ESOPHAGEAL cancer , *CANCER cell proliferation , *CELL migration , *MUCINS , *DISEASE progression , *GENE expression , *CARCINOGENESIS , *ADENOCARCINOMA - Abstract
Abstract: MUC4 is a membrane-bound mucin known to participate in tumor progression. It has been shown that MUC4 pattern of expression is modified during esophageal carcinogenesis, with a progressive increase from metaplastic lesions to adenocarcinoma. The principal cause of development of esophageal adenocarcinoma is the gastro-esophageal reflux, and MUC4 was previously shown to be upregulated by several bile acids present in reflux. In this report, our aim was thus to determine whether MUC4 plays a role in biological properties of human esophageal cancer cells. For that stable MUC4-deficient cancer cell lines (shMUC4 cells) were established using a shRNA approach. In vitro (proliferation, migration and invasion) and in vivo (tumor growth following subcutaneous xenografts in SCID mice) biological properties of shMUC4 cells were analyzed. Our results show that shMUC4 cells were less proliferative, had decreased migration properties and did not express S100A4 protein when compared with MUC4 expressing cells. Absence of MUC4 did not impair shMUC4 invasiveness. Subcutaneous xenografts showed a significant decrease in tumor size when cells did not express MUC4. Altogether, these data indicate that MUC4 plays a key role in proliferative and migrating properties of esophageal cancer cells as well as is a tumor growth promoter. MUC4 mucin appears thus as a good therapeutic target to slow-down esophageal tumor progression. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
29. Mucins and Pancreatic Cancer.
- Author
-
Jonckheere, Nicolas, Skrypek, Nicolas, and Van Seuningen, Isabelle
- Subjects
- *
MUCINS , *PANCREATIC cancer , *BIOMARKERS , *GLYCOPROTEINS , *CANCER cells , *CARCINOGENESIS - Abstract
Pancreatic cancer is characterized by an often dramatic outcome (five year survival < 5%) related to a late diagnosis and a lack of efficient therapy. Therefore, clinicians desperately need new biomarkers and new therapeutic tools to develop new efficient therapies. Mucins belong to an ever increasing family of O-glycoproteins. Secreted mucins are the main component of mucus protecting the epithelia whereas membrane-bound mucins are thought to play important biological roles in cell-cell and cell-matrix interactions, in cell signaling and in modulating biological properties of cancer cells. In this review, we will focus on the altered expression pattern of mucins in pancreatic cancer, from the early neoplastic lesion Pancreatic Intraepithelial Neoplasia (PanIN) to invasive pancreatic carcinomas, and the molecular mechanisms (including genetic and epigenetic regulation) and signaling pathways known to control their expression. Moreover, we will discuss the recent advances about the biology of both secreted and membrane-bound mucins and their key roles in pancreatic carcinogenesis and resistance to therapy. Finally, we will discuss exciting opportunities that mucins offer as potential therapeutic targets in pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers
- Author
-
Jonckheere, Nicolas and Van Seuningen, Isabelle
- Subjects
- *
MUCINS , *CELLULAR signal transduction , *CELL communication , *GENE expression , *GENETIC transcription , *CARCINOMA , *CELLULAR control mechanisms , *CELL membranes - Abstract
Abstract: The membrane-bound mucins belong to an ever-increasing family of O-glycoproteins. Based on their structure and localization at the cell surface they are thought to play important biological roles in cell–cell and cell–matrix interactions, in cell signalling and in modulating biological properties of cancer cells. Among them, MUC1 and MUC4 mucins are best characterized. Their altered expression in cancer (overexpression in the respiratory, gastro-intestinal, urogenital and hepato-biliary tracts) indicates an important role for these membrane-bound mucins in tumour progression, metastasis, cancer cell resistance to chemotherapeutics drugs and as specific markers of epithelial cancer cells. Some mechanisms responsible for MUC1 and MUC4 role in tumour cell properties have been deciphered recently. However, much remains to be done in order to understand the molecular mechanisms and signalling pathways that control the expression of membrane-bound mucins during the different steps of tumour progression toward adenocarcinoma and evaluate their potential as prognostic/diagnostic markers and as therapeutic tools. In this review we focus on the molecular mechanisms and signalling pathways known to control the expression of membrane-bound mucins in cancer. We will discuss the mechanisms of regulation at the promoter level (including genetic and epigenetic modifications) that may be responsible for the mucin altered pattern of expression in epithelial cancers. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
31. Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma.
- Author
-
Boukrout, Nihad, Souidi, Mouloud, Lahdaoui, Fatima, Duchêne, Belinda, Neve, Bernadette, Coppin, Lucie, Leteurtre, Emmanuelle, Torrisani, Jérôme, Van Seuningen, Isabelle, and Jonckheere, Nicolas
- Subjects
PANCREATIC tumors ,ADENOCARCINOMA ,REVERSE transcriptase polymerase chain reaction ,IN vitro studies ,BIOLOGICAL models ,IN vivo studies ,XENOGRAFTS ,ANIMAL experimentation ,MICRORNA ,PRECIPITIN tests ,CELLULAR signal transduction ,CELL motility ,GENE expression ,TUMOR suppressor genes ,GLYCOPROTEINS ,DESCRIPTIVE statistics ,CELL proliferation ,DNA-binding proteins ,POLYMERASE chain reaction ,CELL lines ,MICE - Abstract
Simple Summary: We aimed at characterizing microRNAs activated downstream of MUC4-associated signaling in pancreatic adenocarcinoma. We investigated the MUC4-miR-210-3p reciprocal regulation and deciphered miR-210-3p biological roles in vitro and in vivo. We showed a MUC4-miR-210-3p negative feedback loop that involves NF-κB in PDAC-derived cells and the miR-210-3p anti-tumoral functions, suggesting a complex balance between antagonistic pro-oncogenic functions of the oncomucin MUC4 and anti-tumoral roles of the miR-210-3p. Background: Pancreatic adenocarcinoma (PDAC) is a deadly cancer with an extremely poor prognosis. MUC4 membrane-bound mucin is neoexpressed in early pancreatic neoplastic lesions and is associated with PDAC progression and chemoresistance. In cancers, microRNAs (miRNAs, small noncoding RNAs) are crucial regulators of carcinogenesis, chemotherapy response and even metastatic processes. In this study, we aimed at identifying and characterizing miRNAs activated downstream of MUC4-associated signaling in pancreatic adenocarcinoma. MiRnome analysis comparing MUC4-KD versus Mock cancer cells showed that MUC4 inhibition impaired miR-210-3p expression. Therefore, we aimed to better understand the miR-210-3p biological roles. Methods: miR-210-3p expression level was analyzed by RT-qPCR in PDAC-derived cell lines (PANC89 Mock and MUC4-KD, PANC-1 and MiaPACA-2), as well as in mice and patients tissues. The MUC4-miR-210-3p regulation was investigated using luciferase reporter construct and chromatin immunoprecipitation experiments. Stable cell lines expressing miR-210-3p or anti-miR-210-3p were established using CRISPR/Cas9 technology or lentiviral transduction. We evaluated the biological activity of miR-210-3p in vitro by measuring cell proliferation and migration and in vivo using a model of subcutaneous xenograft. Results: miR-210-3p expression is correlated with MUC4 expression in PDAC-derived cells and human samples, and in pancreatic PanIN lesions of Pdx1-Cre; LstopL-KrasG12D mice. MUC4 enhances miR-210-3p expression levels via alteration of the NF-κB signaling pathway. Chromatin immunoprecipitation experiments showed p50 NF-κB subunit binding on miR-210-3p promoter regions. We established a reciprocal regulation since miR-210-3p repressed MUC4 expression via its 3′-UTR. MiR-210-3p transient transfection of PANC89, PANC-1 and MiaPACA-2 cells led to a decrease in cell proliferation and migration. These biological effects were validated in cells overexpressing or knocked-down for miR-210-3p. Finally, we showed that miR-210-3p inhibits pancreatic tumor growth and proliferation in vivo. Conclusion: We identified a MUC4-miR-210-3p negative feedback loop in early-onset PDAC, but also revealed new functions of miR-210-3p in both in vitro and in vivo proliferation and migration of pancreatic cancer cells, suggesting a complex balance between MUC4 pro-oncogenic roles and miR-210-3p anti-tumoral effects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis.
- Author
-
Stoup, Nicolas, Liberelle, Maxime, Schulz, Céline, Cavdarli, Sumeyye, Vasseur, Romain, Magnez, Romain, Lahdaoui, Fatima, Skrypek, Nicolas, Peretti, Fabien, Frénois, Frédéric, Thuru, Xavier, Melnyk, Patricia, Renault, Nicolas, Jonckheere, Nicolas, Lebègue, Nicolas, and Van Seuningen, Isabelle
- Subjects
PANCREATIC tumors ,IN vitro studies ,IN vivo studies ,CELL migration ,EPIDERMAL growth factor ,ONCOGENES ,WESTERN immunoblotting ,MICROBIOLOGICAL assay ,ONE-way analysis of variance ,BIOINFORMATICS ,GLYCOPROTEINS ,CELL proliferation ,RESEARCH funding ,CELL lines - Abstract
Simple Summary: A feature of pancreatic cancer (PC) is the frequent overexpression of tyrosine kinase membrane receptor HER2 along with its membrane partner the MUC4 oncomucin in the early stages of the pancreatic carcinogenesis. However, therapeutic approaches targeting HER2 in PC are not efficient. MUC4 could indeed represent an alternative therapeutic strategy to target HER2 signaling pathway, but this approach needs to characterize MUC4/HER2 interaction at the molecular level. In this study, we successfully showed the impact of the EGF domains of MUC4 on HER2 binding affinity and demonstrated their "growth factor-like" biological activities in PC cells. Moreover, homology models of the MUC4
EGF /HER2 complexes allowed identification of binding hotspots mediating binding affinity with HER2 and PC cell proliferation. These results allow a better understanding of the mechanisms involved in the MUC4/HER2 complex formation and may lead to the design of potential MUC4/HER2 inhibitors. The HER2 receptor and its MUC4 mucin partner form an oncogenic complex via an extracellular region of MUC4 encompassing three EGF domains that promotes tumor progression of pancreatic cancer (PC) cells. However, the molecular mechanism of interaction remains poorly understood. Herein, we decipher at the molecular level the role and impact of the MUC4EGF domains in the mediation of the binding affinities with HER2 and the PC cell tumorigenicity. We used an integrative approach combining in vitro bioinformatic, biophysical, biochemical, and biological approaches, as well as an in vivo study on a xenograft model of PC. In this study, we specified the binding mode of MUC4EGF domains with HER2 and demonstrate their "growth factor-like" biological activities in PC cells leading to stimulation of several signaling proteins (mTOR pathway, Akt, and β-catenin) contributing to PC progression. Molecular dynamics simulations of the MUC4EGF /HER2 complexes led to 3D homology models and identification of binding hotspots mediating binding affinity with HER2 and PC cell proliferation. These results will pave the way to the design of potential MUC4/HER2 inhibitors targeting the EGF domains of MUC4. This strategy will represent a new efficient alternative to treat cancers associated with MUC4/HER2 overexpression and HER2-targeted therapy failure as a new adapted treatment to patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. The Human Mucin MUC4 Is Transcriptionally Regulated by Caudal-related Homeobox, Hepatocyte Nuclear Factors, Forkhead Box A, and GATA Endodermal Transcription Factors in Epithelial Cancer Cells.
- Author
-
Jonckheere, Nicolas, Vincent, Audrey, Perrais, Michaël, Ducourouble, Marie-Paule, Korteland-van Male, Anita, Aubert, Jean-Pierre, Pigny, Pascal, Carraway, Kermit L., Freund, Jean-Noël, Renes, Ingrid B., and Van Seuningen, Isabelle
- Subjects
- *
MUCINS , *HOMEOBOX genes , *LIVER cells , *TRANSCRIPTION factors , *CANCER cells - Abstract
The human gene MUC4 encodes a large transmembrane mucin that is developmentally regulated and expressed along the undifferentiated pseudostratified epithelium, as early as 6.5 weeks during fetal development. Immunohistochemical analysis of Muc4 expression in developing mouse lung and gastrointestinal tract showed a different spatio-temporal pattern of expression before and after cytodifferentiation. The molecular mechanisms governing MUC4 expression during development are, however, unknown. Hepatocyte nuclear factors (HNF), forkhead box A (FOXA), GATA, and caudal-related homeobox transcription factors (TFs) are known to control cell differentiation of gut endoderm derived-tissues during embryonic development. They also control the expression of cell- and tissue-specific genes and may thus control MUC4 expression. To test this hypothesis, we studied and deciphered the molecular mechanisms responsible for MUC4 transcriptional regulation by these TFs. Experiments using small interfering RNA, cell co-transfection, and site-directed mutagenesis indicated that MUC4 is regulated at the transcriptional level by CDX-1 and -2, HNF-1α and -11β, FOXA1/A2, HNF-41α and -41γ, and GATA-4, -5, and -6 factors in a cell-specific manner. Binding of TFs was assessed by chromatin immunoprecipitation, and gel-shift assays. Altogether, these results demonstrate that MUC4 is a target gene of endodermal TFs and thus point out an important role for these TFs in regulating MUC4 expression during epithelial differentiation during development, cancer, and repair. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
34. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-ß in pancreatic carcinogenesis.
- Author
-
Jonckheere, Nicolas, Perrais, Michaël, Mariette, Christophe, Batra, Surinder K., Aubert, Jean-Pierre, Pigny, Pascal, and Van Seuningen, Isabelle
- Subjects
MUCINS ,PANCREATIC cancer ,GENETIC transcription ,ACETYLATION ,CARCINOGENESIS - Abstract
MUC4: encodes a large transmembrane mucin that is overexpressed in pancreatic adenocarcinomas. The molecular mechanisms responsible for that altered pattern of expression are unknown. TGF-ß, a pleiotropic cytokine, regulates numerous genes involved in pancreatic carcinogenesis via activation of the Smads proteins and MUC4 promoter is rich in Smad-binding elements. Our aim was to study whether the regulation of MUC4 expression by TGF-ß in pancreatic cancer cells was strictly dependent on Smad4 activity. Three pancreatic cancer cell lines, CAPAN-1 (MUC4+/Smad4-), CAPAN-2 (MUC4+/Smad4+) and PANC-1 (MUC4-/Smad4+), were used. By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-ß, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-ß induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4. When Smad4 is mutated and inactive, TGF-ß activates MUC4 expression via MAPK, PI3K and PKA signaling pathways. Absence of expression in PANC-1 cells is due to histone deacetylation. Altogether, these results indicate that upregulation of MUC4 by TGF-ß is restricted to well-differentiated pancreatic cancer cells, and point out a novel mechanism for TGF-ß as a key molecule in targeting MUC4 overexpression in pancreatic adenocarcinomas.Oncogene (2004) 23, 5729-5738. doi:10.1038/sj.onc.1207769 Published online 7 June 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
35. Human MUC2 Mucin Gene Is Transcriptionally Regulated by Cdx Homeodomain Proteins in Gastrointestinal Carcinoma Cell Lines.
- Author
-
Mesquita, Patrícia, Jonckheere, Nicolas, Almeida, Raquel, Ducourouble, Marie-Paule, Serpa, Jacinta, Silva, Elisabete, Pigny, Pascal, Silva, Filipe Santos, Reis, Celso, Silberg, Debra, Van Seuningen, Isabelle, and David, Leonor
- Subjects
- *
GASTROINTESTINAL diseases , *CANCER , *CELL lines , *METAPLASIA , *MUCINS , *TRANSCRIPTION factors - Abstract
In intestinal metaplasia and 30% of gastric carcinomas, MUC2 intestinal mucin and the intestine-specific transcription factors Cdx-1 and Cdx-2 are aberrantly expressed. The involvement of Cdx-1 and Cdx-2 in the intestinal development and their role in transcription of several intestinal genes support the hypothesis that Cdx-1 and/or Cdx-2 play important roles in the aberrant intestinal differentiation program of intestinal metaplasia and gastric carcinoma. To clarify the mechanisms of transcriptional regulation of the MUC2 mucin gene in gastric cells, pGL3 deletion constructs covering 2.6 kb of the human MUC2 promoter were used in transient transfection assays, enabling us to identify a relevant region for MUC2 transcription in all gastric cell lines. To evaluate the role of Cdx-1 and Cdx-2 in MUC2 transcription we performed co-transfection experiments with expression vectors encoding Cdx-1 and Cdx-2. In two of the four gastric carcinoma cell lines and in all colon carcinoma cell lines we observed transactivation of the MUC2 promoter by Cdx-2. Using gel shift assays we identified two Cdx-2 binding sites at -177/-171 and -191/-187. Only simultaneous mutation of the two sites resulted in inhibition of Cdx-2-mediated transactivation of MUC2 promoter, implying that both Cdx-2 sites are active. Finally, stable expression of Cdx-2 in a gastric cell line initially not expressing Cdx-2, led to induction of MUC2 expression. In conclusion, this work demonstrates that Cdx-2 activates the expression of MUC2 mucin gene in gastric cells, inducing an intestinal transdifferentiation phenotype that parallels what is observed both in intestinal metaplasia and some gastric carcinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
36. Magnesium transporters: Discovering new potential biomarkers in digestive cancers.
- Author
-
Auwercx, Julie, Rybarczyk, Pierre, Kischel, Philippe, Duthille, Isabelle Dhennin, Chatelain, Denis, Sevestre, Henri, Van Seuningen, Isabelle, Ouadid-Ahidouch, Halima, Jonckheere, Nicolas, and Gautier, Mathieu
- Subjects
TUMOR markers ,GENE expression ,OVERALL survival ,CANCER cell proliferation ,MEMBRANE transport proteins ,CELL migration - Abstract
Purpose: Many epidemiological studies suggest that a bad diet and lifestyle could increase the risk of developing digestive cancer [2-4]. Notably, magnesium (Mg
2+ ) intake decreases over the years and could be linked to the incidence of some digestive cancers such as pancreatic cancer [5]. Mg2+ is essential for cellular physiology, as it regulates a lot of cellular processes. Its homeostasis is regulated by membrane transporters, such as TRPM6, TRPM7, MAGT1, CNNM4, SLC41A1, and MRS2. However, their distribution in tissues from digestive cancers has not been exhaustively studied. This work aims to study Mg2+ transporter transporter expression in digestive cancers and their impact on patient survival. Materials and methods: We analyzed the Mg2+ transporters TRPM6, TRPM7, MAGT1, CNNM1-4, SLC41A1, and MRS2 mRNA relative expression from the TCGA transcriptomic datasets to investigate their expression pattern, combinatory correlation, and their impact on survival in esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), pancreatic adenocarcinoma (PAAD) and colorectal adenocarcinoma (COADREAD). Genotype Tissue Expression (GTEx) and Cancer Genome Atlas (TCGA) datasets were analyzed in this study, using GEPIA2 and RStudio tools. Results: By comparing nontumoral and tumoral tissues, we observed an alteration of Mg2+ transporters expression in most of digestive cancers. MAGT1 and CNNM4 are overexpressed in all digestive cancers and are negatively correlated with overall-survival and in disease-free in PAAD patients. High TRPM6 was correlated with a better outcome in those patients. Interestingly, we identified a gene signature involving MAGT1, CNNM4 and TRPM7. This signature is associated with poor prognosis in some digestive cancers, like PAAD, ESCA or COADREAD. Conclusion: Our work suggests the importance of Mg2+ transporters such as MAGT1, TRPM7, and CNNM4 as potential new biomarkers in digestive cancers. More analyses are required to evaluate the functional interaction among those proteins and their impact on cancer processes such as cell proliferation, migration, or invasion. [ABSTRACT FROM AUTHOR]- Published
- 2021
37. The EGF domains of MUC4 oncomucin interact with ErbB2 and mediate tumorigenic activity of cancer cells represent new potential therapeutic targets.
- Author
-
Stoup, Nicolas, Liberelle, Maxime, Schulz, Céline, Vasseur, Romain, Magnez, Romain, Thuru, Xavier, Melnyk, Patricia, Renault, Nicolas, Jonckheere, Nicolas, Lebegue, Nicolas, and Van Seuningen, Isabelle
- Published
- 2021
- Full Text
- View/download PDF
38. Mg 2+ Transporters in Digestive Cancers.
- Author
-
Auwercx, Julie, Rybarczyk, Pierre, Kischel, Philippe, Dhennin-Duthille, Isabelle, Chatelain, Denis, Sevestre, Henri, Van Seuningen, Isabelle, Ouadid-Ahidouch, Halima, Jonckheere, Nicolas, and Gautier, Mathieu
- Abstract
Despite magnesium (Mg
2+ ) representing the second most abundant cation in the cell, its role in cellular physiology and pathology is far from being elucidated. Mg2+ homeostasis is regulated by Mg2+ transporters including Mitochondrial RNA Splicing Protein 2 (MRS2), Transient Receptor Potential Cation Channel Subfamily M, Member 6/7 (TRPM6/7), Magnesium Transporter 1 (MAGT1), Solute Carrier Family 41 Member 1 (SCL41A1), and Cyclin and CBS Domain Divalent Metal Cation Transport Mediator (CNNM) proteins. Recent data show that Mg2+ transporters may regulate several cancer cell hallmarks. In this review, we describe the expression of Mg2+ transporters in digestive cancers, the most common and deadliest malignancies worldwide. Moreover, Mg2+ transporters' expression, correlation and impact on patient overall and disease-free survival is analyzed using Genotype Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) datasets. Finally, we discuss the role of these Mg2+ transporters in the regulation of cancer cell fates and oncogenic signaling pathways. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
39. Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival.
- Author
-
Jonckheere, Nicolas, Auwercx, Julie, Hadj Bachir, Elsa, Coppin, Lucie, Boukrout, Nihad, Vincent, Audrey, Neve, Bernadette, Gautier, Mathieu, Treviño, Victor, and Van Seuningen, Isabelle
- Subjects
- *
GLYCOPROTEIN analysis , *ADENOCARCINOMA , *CLUSTER analysis (Statistics) , *COMPARATIVE studies , *GENE mapping , *GLYCOPROTEINS , *MESSENGER RNA , *PANCREATIC tumors , *SURVIVAL analysis (Biometry) , *TUMOR markers , *GENE expression profiling , *DESCRIPTIVE statistics - Abstract
Simple Summary: Pancreatic cancer has a dramatic outcome (survival curve < 6 months) that is the consequence of late diagnosis and the lack of efficient therapy. We investigated the relationship between the 22 mucin gene expression and the patient survival in pancreatic cancer datasets that provide a comprehensive mapping of transcriptomic alterations occurring during carcinogenesis. Using unsupervised hierarchical clustering analysis of mucin gene expression patterns, we identified two major clusters of patients: atypical mucin signature (#1; MUC15, MUC14/EMCN, and MUC18/MCAM) and membrane-bound mucin signature (#2; MUC1, -4, -16, -17, -20, and -21). The signature #2 is associated with shorter overall survival, suggesting that the pattern of membrane-bound mucin expression could be a new prognostic marker for PDAC patients. Mucins are commonly associated with pancreatic ductal adenocarcinoma (PDAC) that is a deadly disease because of the lack of early diagnosis and efficient therapies. There are 22 mucin genes encoding large O-glycoproteins divided into two major subgroups: membrane-bound and secreted mucins. We investigated mucin expression and their impact on patient survival in the PDAC dataset from The Cancer Genome Atlas (PAAD-TCGA). We observed a statistically significant increased messenger RNA (mRNA) relative level of most of the membrane-bound mucins (MUC1/3A/4/12/13/16/17/20), secreted mucins (MUC5AC/5B), and atypical mucins (MUC14/18) compared to normal pancreas. We show that MUC1/4/5B/14/17/20/21 mRNA levels are associated with poorer survival in the high-expression group compared to the low-expression group. Using unsupervised clustering analysis of mucin gene expression patterns, we identified two major clusters of patients. Cluster #1 harbors a higher expression of MUC15 and atypical MUC14/MUC18, whereas cluster #2 is characterized by a global overexpression of membrane-bound mucins (MUC1/4/16/17/20/21). Cluster #2 is associated with shorter overall survival. The patient stratification appears to be independent of usual clinical features (tumor stage, differentiation grade, lymph node invasion) suggesting that the pattern of membrane-bound mucin expression could be a new prognostic marker for PDAC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. Epigenetic Regulation by lncRNAs: An Overview Focused on UCA1 in Colorectal Cancer.
- Author
-
Neve, Bernadette, Jonckheere, Nicolas, Vincent, Audrey, and Van Seuningen, Isabelle
- Subjects
- *
CANCER chemotherapy , *CELL cycle , *CELL lines , *COLON tumors , *GENE expression , *METASTASIS , *ONCOGENES , *RNA , *DISEASE progression , *MICRORNA , *EPIGENOMICS , *GENETICS ,RECTUM tumors - Abstract
Colorectal cancers have become the second leading cause of cancer-related deaths. In particular, acquired chemoresistance and metastatic lesions occurring in colorectal cancer are a major challenge for chemotherapy treatment. Accumulating evidence shows that long non-coding (lncRNAs) are involved in the initiation, progression, and metastasis of cancer. We here discuss the epigenetic mechanisms through which lncRNAs regulate gene expression in cancer cells. In the second part of this review, we focus on the role of lncRNA Urothelial Cancer Associated 1 (UCA1) to integrate research in different types of cancer in order to decipher its putative function and mechanism of regulation in colorectal cancer cells. UCA1 is highly expressed in cancer cells and mediates transcriptional regulation on an epigenetic level through the interaction with chromatin modifiers, by direct regulation via chromatin looping and/or by sponging the action of a diversity of miRNAs. Furthermore, we discuss the role of UCA1 in the regulation of cell cycle progression and its relation to chemoresistance in colorectal cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727.
- Author
-
Drubay, Vincent, Skrypek, Nicolas, Cordiez, Lucie, Vasseur, Romain, Schulz, Céline, Boukrout, Nihad, Duchêne, Belinda, Coppin, Lucie, Van Seuningen, Isabelle, and Jonckheere, Nicolas
- Subjects
ADENOCARCINOMA ,ANTIMETABOLITES ,BIOMARKERS ,CELLULAR signal transduction ,DRUG resistance ,GENETIC mutation ,PANCREATIC tumors ,TRANSFORMING growth factors-beta ,TREATMENT effectiveness ,NEURAL pathways ,PHARMACODYNAMICS - Abstract
Pancreatic adenocarcinoma (PDAC) is one of the most deadly cancers in the Western world because of a lack of early diagnostic markers and efficient therapeutics. At the time of diagnosis, more than 80% of patients have metastasis or locally advanced cancer and are therefore not eligible for surgical resection. Pancreatic cancer cells also harbour a high resistance to chemotherapeutic drugs such as gemcitabine that is one of the main palliative treatments for PDAC. Proteins involved in TGF-β signaling pathway (SMAD4 or TGF-βRII) are frequently mutated in PDAC (50–80%). TGF-β signalling pathway plays antagonistic roles during carcinogenesis by initially inhibiting epithelial growth and later promoting the progression of advanced tumors and thus emerged as both tumor suppressor and oncogenic pathways. In order to decipher the role of TGF-β in pancreatic carcinogenesis and chemoresistance, we generated CAPAN-1 and CAPAN-2 cell lines knocked down for TGF-βRII (first actor of TGF-β signaling). The impact on biological properties of these TGF-βRII-KD cells was studied both in vitro and in vivo. We show that TGF-βRII silencing alters tumor growth and migration as well as resistance to gemcitabine. TGF-βRII silencing also leads to S727 STAT3 and S63 c-Jun phosphorylation, decrease of MRP3 and increase of MRP4 ABC transporter expression and induction of a partial EMT phenotype. These markers associated with TGF-β signaling pathways may thus appear as potent therapeutic tools to better treat/manage pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. T1998 The Muc4 Membrane-Bound Mucin Alters In Vitro and In Vivo Biological Properties of Human Pancreatic Cancer Cells.
- Author
-
Jonckheere, Nicolas, Skrypek, Nicolas, Saint-Laurent, Nathalie, Susini, Christiane, and VAN SEUNINGEN, Isabelle
- Published
- 2009
- Full Text
- View/download PDF
43. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
- Author
-
Tréhoux, Solange, Duchêne, Bélinda, Jonckheere, Nicolas, and Van Seuningen, Isabelle
- Subjects
- *
PANCREATIC cancer , *CANCER cells , *MUCINS , *MITOGEN-activated protein kinases , *EPITHELIAL cells , *ADENOCARCINOMA , *CELLULAR signal transduction - Abstract
MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To this aim, we undertook to study MUC1 biological effects on pancreatic cancer cells and identify pathways mediating these effects. Our in vitro experiments indicate that inhibiting MUC1 expression decreases cell proliferation, cell migration and invasion, cell survival and increases cell apoptosis. Moreover, lack of MUC1 in these cells profoundly altered their sensitivity to gemcitabine and 5-Fluorouracil chemotherapeutic drugs. In vivo MUC1-KD cell xenografts in SCID mice grew slower. Altogether, we show that MUC1 oncogenic mucin alters proliferation, migration, and invasion properties of pancreatic cancer cells and that these effects are mediated by p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells
- Author
-
van der Sluis, Maria, Melis, Monique H.M., Jonckheere, Nicolas, Ducourouble, Marie-Paule, Büller, Hans A., Renes, Ingrid, Einerhand, Alexandra W.C., and Van Seuningen, Isabelle
- Subjects
- *
TRANSCRIPTION factors , *PROTEINS , *SMALL intestine , *GENETIC regulation - Abstract
Abstract: MUC2, the major mucin in the intestine, is expressed early during development and shows an altered expression pattern in intestinal bowel diseases. However, the mechanisms responsible for MUC2 expression in the intestine during these events are largely unknown. Having found putative GATA binding sites in the murine Muc2 promoter and that GATA-4 is expressed in Muc2-expressing goblet cells of the mouse small intestine, we undertook to study its regulation by this transcription factor. A panel of deletion mutants made in pGL3 vector and covering 2.2kb of the promoter were used to transfect the murine CMT-93 colorectal cancer cell line. The role of GATA-4 on Muc2 gene regulation was investigated by RT-PCR and co-transfections in the presence of expression vectors encoding either wild-type or mutated GATA-4 or by mutating the GATA-4 site identified within Muc2 promoter. Four GATA-4 cis-elements were identified in the promoter by EMSA and Muc2 promoter was efficiently activated when GATA-4 was overexpressed in the cells with a loss of transactivation when those sites were either mutated or a mutated form of GATA-4 was used. Altogether, these results identify Muc2, a goblet cell marker, as a new target gene of GATA-4 and point out an important role for this factor in Muc2 expression in the intestine. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
45. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
- Author
-
Tréhoux, Solange, Lahdaoui, Fatima, Delpu, Yannick, Renaud, Florence, Leteurtre, Emmanuelle, Torrisani, Jérôme, Jonckheere, Nicolas, and Van Seuningen, Isabelle
- Subjects
- *
PANCREATIC cancer , *MICRORNA , *ONCOGENES , *MUCOPROTEINS ,MUCIN analysis - Abstract
MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To control cancer progression, miRNAs became very recently, major targets and tools to inhibit oncogene expression. Inhibiting MUC1 using miRNAs appears thus as an attractive strategy to reduce cancer progression. However, potent miRNAs and associated mechanisms regulating MUC1 expression remain to be identified. To this aim, we undertook to study MUC1 regulation by miRNAs in pancreatic cancer cells and identify those with tumor suppressive activity. MiRNAs potentially targeting the 3′-UTR, the coding region, or the 5′-UTR of MUC1 were selected using an in silico approach. Our invitro and invivo experiments indicate that miR-29a and miR-330-5p are strong inhibitors of MUC1 expression in pancreatic cancer cells through direct binding to MUC1 3′-UTR. MUC1 regulation by the other selected miRNAs (miR-183, miR-200a, miR-876-3p and miR-939) was found to be indirect. MiR-29a and miR-330-5p are also deregulated in human pancreatic cancer cell lines and tissues and in pancreatic tissues of Kras G12D mice. In vitro, miR-29a and miR-330-5p inhibit cell proliferation, cell migration, cell invasion and sensitize pancreatic cancer cells to gemcitabine. In vivo intra-tumoral injection of these two miRNAs in xenografted pancreatic tumors led to reduced tumor growth. Altogether, we have identified miR-29a and miR-330-5p as two new tumor suppressive miRNAs that inhibit the expression of MUC1 oncogenic mucin in pancreatic cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells.
- Author
-
Gronnier, Caroline, Bruyère, Emilie, Lahdaoui, Fatima, Jonckheere, Nicolas, Perrais, Michaël, Leteurtre, Emmanuelle, Piessen, Guillaume, Mariette, Christophe, and Van Seuningen, Isabelle
- Subjects
- *
ONCOGENIC viruses , *ESOPHAGEAL cancer , *ADENOCARCINOMA , *CELL proliferation , *GENE expression , *XENOGRAFTS , *CELL lines - Abstract
MUC1 is a membrane-bound mucin known to participate in tumor proliferation. It has been shown that MUC1 pattern of expression is modified during esophageal carcinogenesis, with a progressive increase from metaplasia to adenocarcinoma. The principal cause of development of esophageal adenocarcinoma is gastro-esophageal reflux and MUC1 was previously shown to be up-regulated by several bile acids present in reflux. In this report, our aim was thus to determine whether MUC1 plays a role in biological properties of human esophageal cancer cells. For that, a stable MUC1-deficient esophageal cancer cell line was established using a shRNA approach. In vitro (proliferation, migration and invasion) and in vivo (tumor growth following subcutaneous xenografts in SCID mice) biological properties of MUC1-deficient cells were analyzed. Our results show that esophageal cancer cells lacking MUC1 were less proliferative and had decreased migration and invasion properties. These alterations were accompanied by a decreased activity of NFKB p65, Akt and MAPK (p44/42, JNK and p38) pathways. MCM6 and TSG101 tumor-associated markers were also decreased. Subcutaneous xenografts showed a significant decrease in tumor size when cells did not express MUC1. Altogether, the data indicate that MUC1 plays a key role in proliferative, migrating and invasive properties of esophageal cancer cells as well as in tumor growth promotion. MUC1 mucin appears thus as a good therapeutic target to slow down esophageal tumor progression. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Identification of pancreatic adenocarcinoma immune subtype associated with tumor neoantigen from aberrant alternative splicing.
- Author
-
Du Q, Yu Z, Zhang Z, Yang J, Jonckheere N, Shi S, Wang W, Xu J, Liu J, and Yu X
- Abstract
Background: Pancreatic adenocarcinoma (PAAD) is referred to as an immunologically "cold" tumor that responds poorly to immunotherapy. A fundamental theory that explains the low immunogenicity of PAAD is the dramatically low tumor mutation burden (TMB) of PAAD tumors, which fails to induce sufficient immune response. Alternative splicing of pre-mRNA, which could alter the proteomic diversity of many cancers, has been reported to be involved in neoantigen production. Therefore, we aim to identify novel PAAD antigens and immune subtypes through systematic bioinformatics research., Methods: Data for splicing analysis were downloaded from The Cancer Genome Atlas (TCGA) SpliceSeq database. Among the available algorithms, we chose CIBERSORT to evaluate the immune cell distribution among PAADs. The TCGA-PAAD expression matrix was used to construct a co-expression network. Single-cell analysis was performed based on the Seurat workflow., Results: Integrated analysis of aberrantly upregulated genes, alternatively spliced genes, genes associated with nonsense-mediated RNA decay (NMD) factors, antigen presentation and overall survival (OS) in TCGA-PAAD revealed that PLEC is a promising neoantigen for PAAD-targeted therapy. We identified a C2 TCGA-PAAD subtype that had better prognosis and more CD8
+ T-cell infiltration. We propose a novel immune subtyping system for PAAD to indicate patient prognosis and opportunities for immunotherapy, such as immune checkpoint (ICP) inhibitors., Conclusions: In conclusion, the present study used a transcriptome-guided approach to screen neoantigen candidates based on alternative splicing, NMD factors, and antigen-presenting signatures for PAAD. A prognosis model with guidance of immunotherapy will aid in patient selection for appropriate treatment., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-340/coif). The authors have no conflicts of interest to declare., (2024 Journal of Gastrointestinal Oncology. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
48. EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?
- Author
-
Liberelle M, Jonckheere N, Melnyk P, Van Seuningen I, and Lebègue N
- Subjects
- Amino Acid Sequence, Animals, Antineoplastic Agents administration & dosage, Antineoplastic Agents metabolism, Cell Membrane drug effects, Drug Delivery Systems methods, Epidermal Growth Factor antagonists & inhibitors, Epidermal Growth Factor chemistry, Humans, Mucins antagonists & inhibitors, Mucins chemistry, Protein Structure, Secondary, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 chemistry, Signal Transduction physiology, Cell Membrane metabolism, Drug Delivery Systems trends, Epidermal Growth Factor metabolism, Mucins metabolism, Receptor, ErbB-2 metabolism, Signal Transduction drug effects
- Abstract
Membrane-bound mucins belong to a heterogeneous family of large O-glycoproteins involved in numerous cancers and inflammatory diseases of the epithelium. Some of them are also involved in protein-protein interactions, with receptor tyrosine kinase ErbB2, and fundamental and clinical data showed that these complexes have a detrimental impact on cancer outcome, thus raising interest in therapeutic targeting. This paper aims to demonstrate that MUC3, MUC4, MUC12, MUC13, and MUC17 have a common evolutionary origin and share a common structural organization with EGF-like and SEA domains. Theoretical structure-function relationship analysis of the conserved domains indicated that the studied membrane-bound mucins share common biological properties along with potential specific functions. Finally, the potential druggability of these complexes is discussed, revealing ErbB2-related pathways of cell signaling to be targeted.
- Published
- 2020
- Full Text
- View/download PDF
49. Fine-tuning autophagy in pancreatic adenocarcinoma: full blockage is required.
- Author
-
Jonckheere N and Van Seuningen I
- Abstract
Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.
- Published
- 2019
- Full Text
- View/download PDF
50. Flagellin-Mediated Protection against Intestinal Yersinia pseudotuberculosis Infection Does Not Require Interleukin-22.
- Author
-
Porte R, Van Maele L, Muñoz-Wolf N, Foligné B, Dumoutier L, Tabareau J, Cayet D, Gosset P, Jonckheere N, Van Seuningen I, Chabalgoity JA, Simonet M, Lamkanfi M, Renauld JC, Sirard JC, and Carnoy C
- Subjects
- Animals, Disease Models, Animal, Female, Flagellin administration & dosage, Interleukins genetics, Intestinal Mucosa microbiology, Lipopolysaccharides immunology, Mice, Mice, Knockout, Recombinant Fusion Proteins, Signal Transduction, Toll-Like Receptors metabolism, Yersinia pseudotuberculosis Infections microbiology, Yersinia pseudotuberculosis Infections mortality, Interleukin-22, Flagellin immunology, Interleukins metabolism, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Yersinia pseudotuberculosis immunology, Yersinia pseudotuberculosis Infections immunology, Yersinia pseudotuberculosis Infections metabolism
- Abstract
Signaling through Toll-like receptors (TLRs), the main receptors in innate immunity, is essential for the defense of mucosal surfaces. It was previously shown that systemic TLR5 stimulation by bacterial flagellin induces an immediate, transient interleukin-22 (IL-22)-dependent antimicrobial response to bacterial or viral infections of the mucosa. This process was dependent on the activation of type 3 innate lymphoid cells (ILCs). The objective of the present study was to analyze the effects of flagellin treatment in a murine model of oral infection with Yersinia pseudotuberculosis (an invasive, Gram-negative, enteropathogenic bacterium that targets the small intestine). We found that systemic administration of flagellin significantly increased the survival rate after intestinal infection (but not systemic infection) by Y. pseudotuberculosis This protection was associated with a low bacterial count in the gut and the spleen. In contrast, no protection was afforded by administration of the TLR4 agonist lipopolysaccharide, suggesting the presence of a flagellin-specific effect. Lastly, we found that TLR5- and MyD88-mediated signaling was required for the protective effects of flagellin, whereas neither lymphoid cells nor IL-22 was involved., (Copyright © 2017 American Society for Microbiology.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.